AFP and hepatocellular carcinoma: Additionally, biomarker combinations of PIVKA-II and AFP showed significantly higher clinical performance than AFP, PIVKA-II and AFP-L3 combined (AUCs 0.753 and 0.690, respectively; p = 0.001),32 further signifying that AFP-L3 may have a negligible role in HCC detection.